Top Markets
#1 AntFun AntFun +58.69%
#2 BankrCoin BankrCoin +22.98%
#3 EXOD EXOD +21.04%
#4 ZetaChain ZetaChain +16.29%
#5 Fake World Assets Fake World Assets +14.27%
#6 Venom Venom +12.87%
#7 CARV CARV +10.82%
#8 StonkBroker StonkBroker +10.81%
#9 Black Phoenix Black Phoenix +10.04%
#10 Phala Phala +9.50%
Coin of the day
AntFun AntFun
Settings
Language
ENGLISH
Currency
USD
Theme
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Rank in Stocks #107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Share Price
$41.14
Last synced: 2026-09-21
Market Cap
$182.76B
Change (1 day)
-7.78%
Change (1 year)
-32.24%
Country
DK
Trade Novo Nordisk A/S (NOVO-B)

Category

Healthcare
P/S ratio for Novo Nordisk A/S (NOVO-B)
P/S ratio as of September 2026 TTM: 3.78
According to Novo Nordisk A/S latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.78. At the end of 2024 the company had a P/S ratio of 9.57.
P/S ratio history for Novo Nordisk A/S from 2000 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 3.78 -19.20%
2025 4.68 -51.16%
2024 9.57 -28.95%
2023 13.47 12.21%
2022 12.01 0.14%
2021 11.99 52.88%
2020 7.84 4.26%
2019 7.52 14.27%
2018 6.58 -10.96%
2017 7.39 28.28%
2016 5.76 -39.48%
2015 9.53 23.95%
2014 7.69 20.58%
2013 6.37 -2.85%
2012 6.56 16.63%
2011 5.62 -6.38%
2010 6.01 54.26%
2009 3.89 6.22%
2008 3.67 -25.10%
2007 4.90 23.93%
2006 3.95 14.37%
2005 3.45 -0.13%
2004 3.46 11.99%
2003 3.09 9.60%
2002 2.82 -43.18%
2001 4.96 6.86%
2000 4.64 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
13.45 255.68%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
6.55 73.32%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
7.18 89.91%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
4.66 23.19%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
5.39 42.48%
US